Vascular Cognitive Impairment & Vascular Dementia Support Protocol
Primary Stack
Core supplements with strongest evidenceImproves cerebral blood flow and has neuroprotective effects; studied specifically for vascular cognitive impairment
Supports brain cell membranes and neurotransmitter function; studied for vascular cognitive disorders
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsDHA is major structural component of brain; anti-inflammatory and vascular protective effects
Supporting Studies (1)
Lower homocysteine levels which contribute to vascular damage and cognitive decline
Deficiency strongly associated with cognitive decline and cerebrovascular disease
Supporting Studies (1)
Brain cell membrane component that supports cognitive function
Supporting Studies (1)
Supports brain energy metabolism and has neuroprotective properties
Supporting Studies (1)
Supports mitochondrial energy production in brain cells
Supporting Studies (1)
Antioxidant with cerebrovascular protective effects; may improve cerebral blood flow
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Vascular cognitive impairment (VCI) refers to cognitive decline caused by problems with blood supply to the brain. It ranges from mild impairment to vascular dementia, the second most common cause of dementia after Alzheimer's disease. It results from strokes (including "silent" strokes), small vessel disease, or chronic reduced blood flow. Risk factors include hypertension, diabetes, high cholesterol, smoking, and heart disease. Executive function (planning, organizing), processing speed, and attention are typically affected more than memory early on.
CRITICAL: VCI requires medical management of vascular risk factors - blood pressure control, diabetes management, cholesterol treatment, smoking cessation, and sometimes blood thinners. See a neurologist for proper evaluation. If you experience sudden confusion, weakness, or speech problems, this may be a stroke - seek emergency care. These supplements support brain health but don't replace medical treatment.
* Ginkgo Biloba (EGb 761) has the most evidence for vascular cognitive impairment. It improves blood flow to the brain, has antioxidant effects, and may protect brain cells. Multiple meta-analyses support its use.
* Citicoline supports brain cell membrane integrity and helps produce neurotransmitters. Studies show benefit for cognitive function after strokes and in vascular cognitive disorders.
* Omega-3 Fatty Acids (especially DHA) are essential for brain structure and function. They have anti-inflammatory effects and support healthy blood vessels.
* B Vitamins (folate, B12, B6) lower homocysteine, an amino acid that damages blood vessels. High homocysteine is a risk factor for both strokes and dementia. B vitamin treatment slows brain atrophy in people with elevated homocysteine.
* Vitamin D deficiency is strongly linked to cognitive decline and stroke risk. Maintaining adequate levels supports brain health.
* Phosphatidylserine is a natural component of brain cell membranes that may support cognitive function.
* Acetyl-L-Carnitine supports brain energy metabolism and has neuroprotective effects.
* CoQ10 supports energy production in brain cells.
* Resveratrol may improve cerebral blood flow and has antioxidant effects.
Expected timeline: Ginkgo and citicoline: improvements may be seen in 4-12 weeks. B vitamins: effects on brain atrophy seen over months to years. These supplements provide ongoing support; cognitive decline from vascular disease may stabilize or slow with proper treatment.
Clinical Perspective
Vascular cognitive impairment (VCI): cognitive impairment attributed to cerebrovascular disease. Spectrum: vascular mild cognitive impairment (VaMCI) to vascular dementia (VaD). Second most common dementia cause (15-20%). Types: multi-infarct dementia, strategic single-infarct dementia, small vessel disease (subcortical ischemic VaD), hypoperfusion. Neuroimaging: white matter hyperintensities, lacunar infarcts, cortical infarcts. Clinical: stepwise decline (multi-infarct) or insidious (small vessel disease). Executive dysfunction, processing speed deficits more prominent than memory early.
CRITICAL: Vascular risk factor management is primary treatment - blood pressure (<130/80), diabetes (HbA1c <7%), lipids (high-intensity statin), smoking cessation, antiplatelet/anticoagulant therapy as indicated. No FDA-approved drugs specifically for VCI. Cholinesterase inhibitors (donepezil) have modest benefit. Mixed dementia (VCI + Alzheimer's) is common. Supplements are ADJUNCTIVE to risk factor control.
* Ginkgo Biloba (B-grade): EGb 761 improves cerebral blood flow, antioxidant, anti-inflammatory. Meta-analysis: benefit for vascular dementia (PMID: 26841731). Cochrane: supports use in dementia and cognitive impairment (PMID: 28612257). 240mg EGb 761 daily. Caution with anticoagulants.
* Citicoline (B-grade): Phosphatidylcholine precursor; neuroprotective, supports membrane repair. Meta-analysis: improves cognitive function in VCI (PMID: 30103600). 1000-2000mg daily.
* Omega-3 Fatty Acids (B-grade): DHA is 40% of brain phospholipids; anti-inflammatory. Systematic review: may slow cognitive decline (PMID: 26890759). 2-3g EPA+DHA daily; high-DHA formula.
* B Vitamins (B-grade): Lower homocysteine (vascular risk factor). Meta-analysis: B vitamins slow cognitive decline in high-homocysteine patients (PMID: 23904588). Systematic review: B vitamins reduce brain atrophy (PMID: 20838622). Check homocysteine; supplement if elevated.
* Vitamin D (B-grade): VDR in brain; deficiency associated with cognitive decline, stroke. Meta-analysis: low vitamin D associated with VCI risk (PMID: 25324330). 2000-4000 IU daily; target 40-60 ng/mL.
* Phosphatidylserine (B-grade): Cell membrane phospholipid. Meta-analysis: improves cognitive function (PMID: 26267908). 100-300mg daily.
* Acetyl-L-Carnitine (B-grade): Mitochondrial support, acetylcholine precursor. Meta-analysis: benefit for cognitive impairment (PMID: 24287502). 1500-3000mg daily.
* CoQ10 (C-grade): Mitochondrial electron transport; antioxidant. Review: potential neuroprotective effect (PMID: 24571521). 200-300mg daily.
* Resveratrol (C-grade): SIRT1 activator; improves cerebral blood flow. Systematic review: potential cognitive benefit (PMID: 28432076). 150-500mg daily.
Biomarker targets: Blood pressure (<130/80), HbA1c (<7%), LDL (<70 if high risk), homocysteine (<10 umol/L), vitamin D (40-60 ng/mL), B12, folate. Cognitive: MoCA, MMSE, executive function tests. Imaging: MRI (white matter lesions, Fazekas score, new infarcts).
Protocol notes: Hypertension control is paramount - single most important modifiable risk factor. Avoid excessive BP lowering in elderly (maintain cerebral perfusion). Statins for secondary prevention. Antiplatelet (aspirin) for non-cardioembolic stroke; anticoagulation for atrial fibrillation. Diabetes control. Smoking cessation. Mediterranean diet. Exercise (cognitive and vascular benefits). Treat sleep apnea. Cognitive rehabilitation. Depression treatment. Caregiver support. Fall prevention. Address polypharmacy. Cholinesterase inhibitors may help, especially if mixed dementia. Avoid anticholinergics, benzodiazepines. Monitor for progression. Driving assessment. Advance care planning. Social engagement important.